- |||||||||| Soliris (eculizumab) / AstraZeneca
Trial completion: EAGLE: Eculizumab in Primary MPGN (clinicaltrials.gov) - Jan 17, 2018
P2, N=10, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Soliris (eculizumab) / AstraZeneca
Trial primary completion date: EAGLE: Eculizumab in Primary MPGN (clinicaltrials.gov) - Oct 19, 2017
P2, N=10, Active, not recruiting,
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Dec 2017
- |||||||||| Soliris (eculizumab) / AstraZeneca
Trial primary completion date: EAGLE: Eculizumab in Primary MPGN (clinicaltrials.gov) - May 31, 2017
P2, N=10, Active, not recruiting,
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Mar 2017 --> Sep 2017
- |||||||||| Soliris (eculizumab) / AstraZeneca
Trial primary completion date: EAGLE: Eculizumab in Primary MPGN (clinicaltrials.gov) - Apr 13, 2016
P2, N=10, Active, not recruiting,
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- |||||||||| Soliris (eculizumab) / AstraZeneca
Enrollment closed: EAGLE: Eculizumab in Primary MPGN (clinicaltrials.gov) - Apr 9, 2015
P2, N=10, Active, not recruiting,
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- |||||||||| recombinant human Complement Receptor Type 1 (CDX-1135) / Celldex
Trial termination: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease (clinicaltrials.gov) - Mar 5, 2014
P1, N=1, Terminated,
Recruiting --> Active, not recruiting Recruiting --> Terminated; Portfolio prioritization due to slow enrollment and variable spectrum of potential complement abnormalities in DDD patients.
|
